📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Jubilant Ingrevia to Acquire 100% Stake in Remidex Pharma for Rs 16.5 Crore
Jubilant Ingrevia Limited has entered into a Share Purchase Agreement to acquire a 100% stake in Remidex Pharma Private Limited for a cash consideration of Rs 16.5 crore. Remidex is a Bangalore-based manufacturer of micronutrient premixes and nutraceuticals with a turnover of Rs 24.27 crore in FY 2024-25. This acquisition is a strategic move to help Jubilant Ingrevia move forward in the value chain within the Human Nutrition space, leveraging its existing leadership in Vitamins B3 and B4. The deal is expected to be completed within 30 days, making Remidex a wholly-owned subsidiary.
Key Highlights
Acquisition of 100% equity stake in Remidex Pharma for a cash consideration of Rs 16.5 crore.
Remidex reported a turnover of Rs 24.27 crore for FY 2024-25, compared to Rs 31.15 crore in FY 2023-24.
Strategic integration to expand into the Human Nutrition premix market using existing Vitamin B3 and B4 production.
Target entity operates a high-grade manufacturing facility in Bangalore with WHO-GMP and FSSC certifications.
The acquisition is expected to be finalized within an indicative period of 30 days.
💼 Action for Investors
Investors should monitor the integration of Remidex as it represents a strategic shift toward higher-margin value-added products in the nutrition segment. While the acquisition size is small relative to Jubilant's scale, it strengthens their competitive position in the nutraceutical supply chain.
Jubilant FoodWorks Commences Production at New Raigad Supply Chain Centre
Jubilant FoodWorks Limited has officially commenced commercial production at its new Supply Chain Centre/Commissary in Raigad, Maharashtra, as of March 11, 2026. Located in the Patalganga MIDC area, this facility is strategically positioned to enhance the company's logistics and distribution efficiency for its restaurant brands. The operationalization of this center is expected to support store expansion and improve delivery timelines in the Western region. This infrastructure investment underscores the company's commitment to strengthening its back-end supply chain to maintain product quality and operational margins.
Key Highlights
Commencement of commercial production at the Raigad, Maharashtra commissary on March 11, 2026
Facility located at Plot No. A2, Isambe Industrial Area, Patalganga MIDC, Tal. Khalapur
New Supply Chain Centre designed to bolster logistics and distribution capabilities for the Western market
Expansion supports the operational scaling of brands like Domino's Pizza, Dunkin', and Popeyes
💼 Action for Investors
Investors should view this as a positive development for long-term operational efficiency and margin protection. Monitor management commentary in upcoming earnings calls for the expected impact on logistics costs and regional store growth targets.
Jubilant FoodWorks Completes Sale of Entire 31.66% Stake in Hashtag Loyalty
Jubilant FoodWorks Limited has officially completed the divestment of its entire 31.66% stake in Hashtag Loyalty Private Ltd. The transaction was finalized on February 20, 2026, following a share purchase agreement signed with founder Karan Chechani in December 2025. Consequently, Hashtag Loyalty has ceased to be an associate company of Jubilant FoodWorks. This exit reflects the company's strategy to streamline its investment portfolio and focus on core operations.
Key Highlights
Successfully completed the sale of 31.66% equity stake in Hashtag Loyalty Private Ltd.
The transaction was executed with Mr. Karan Chechani, one of the original founders of Hashtag.
Hashtag Loyalty ceased to be an associate company effective February 20, 2026.
The divestment follows the initial execution of the share purchase agreement on December 29, 2025.
💼 Action for Investors
Investors should note this as a strategic exit from a non-core associate investment. Monitor upcoming quarterly results for any realized gains or losses from this transaction.
UBL Partners with Soufflet Malt for New 110,000 Tonne Malthouse in Rajasthan
United Breweries Limited (UBL) has partnered with Soufflet Malt to build a state-of-the-art malthouse in South Rajasthan with an initial capacity of 110,000 tonnes per year. The facility, expected to be commissioned by early 2028, will secure high-quality malt for UBL's core brands like Kingfisher and Heineken. The project includes plans to double capacity in a second phase and will source up to 250,000 tonnes of barley annually from over 50,000 Indian farmers. This strategic backward integration is designed to strengthen UBL's supply chain and support its long-term growth ambitions in the Indian beer market.
Key Highlights
Initial malt production capacity of 110,000 tonnes per year with plans to double in Phase 2
Facility commissioning expected in early 2028 in South Rajasthan
Strategic sourcing of 250,000 tonnes of barley annually from 50,000+ local farmers
Creation of 400 direct/indirect jobs and 700 supply chain positions
Focus on sustainability with zero liquid discharge and advanced water management systems
💼 Action for Investors
Investors should view this as a positive long-term strategic move to secure raw material supply and improve margin stability through backward integration. While the full benefits will only materialize after 2028, it reinforces UBL's market leadership and commitment to sustainable growth.
Jubilant Foodworks' Commercial Paper Rating Reaffirmed at CRISIL A1+; Limit Doubled to ₹200 Cr
CRISIL has reaffirmed the 'CRISIL A1+' rating for Jubilant Foodworks' Commercial Paper program as of February 19, 2026. Significantly, the rated amount for this instrument has been enhanced from INR 100 crore to INR 200 crore. This reaffirmation at the highest possible short-term rating level underscores the company's robust liquidity and strong credit profile. The increased limit provides the company with greater flexibility for short-term funding requirements and working capital management.
Key Highlights
CRISIL reaffirmed the 'CRISIL A1+' rating for the company's Commercial Paper program.
The total rated amount for the instrument was doubled from INR 100 Crore to INR 200 Crore.
The rating action reflects strong financial health and the highest degree of safety regarding timely payment of debt.
The enhancement in the borrowing limit suggests increased capacity for short-term liquidity if required for operations.
💼 Action for Investors
The reaffirmation of the highest credit rating is a positive indicator of financial stability. Investors should view this as a sign of strong creditworthiness and efficient liquidity management.
JUBLCPL Q3 FY26 Revenue Up 13.4% to ₹451 Cr; 9M Net Profit Surges 50% YoY
Jubilant Agri and Consumer Products Limited (JUBLCPL) reported a 13.4% YoY growth in consolidated revenue for Q3 FY26, reaching ₹450.99 crore. While Q3 net profit remained relatively flat at ₹21.52 crore due to higher material costs and an exceptional item of ₹3.83 crore, the nine-month (9M) performance was robust with net profit rising 50.4% to ₹107.93 crore. A key positive is the P&K Fertilizers segment, which turned around from a loss of ₹5.73 crore in Q3 FY25 to a profit of ₹8.50 crore in Q3 FY26.
Key Highlights
Consolidated revenue for Q3 FY26 increased to ₹45,099 Lakhs from ₹39,752 Lakhs in the previous year.
9M FY26 Net Profit grew significantly by 50.4% YoY to ₹10,793 Lakhs.
P&K Fertilizers segment reported a turnaround profit of ₹850 Lakhs vs a loss of ₹573 Lakhs in Q3 FY25.
Performance Polymers & Chemicals remains the largest segment with Q3 revenue of ₹29,459 Lakhs.
Finance costs for the 9M period reduced sharply to ₹502 Lakhs from ₹1,127 Lakhs YoY.
💼 Action for Investors
Investors should take note of the significant improvement in the fertilizer segment's margins and the overall reduction in finance costs. The strong 9M profit growth suggests improving operational efficiency, making it a positive stock to monitor for long-term consistency.
Jubilant Foodworks Q3 FY26: Consolidated Revenue Up 13.3%, EBITDA Grows 20% YoY
Jubilant Foodworks reported a robust Q3 FY26 with consolidated revenue reaching ₹24.4 billion, a 13.3% YoY increase. Domino's India maintained positive momentum with 5% LFL growth on a high base, while India EBITDA margins expanded by 110 bps to 20.5%. The company aggressively expanded its network by adding 114 stores during the quarter, bringing the total count to nearly 3,600. Management highlighted that the Turkey business is now self-sustaining and servicing its acquisition debt through internal cash flows.
Key Highlights
Consolidated revenue grew 13.3% YoY to ₹24.4 billion with a 20% increase in reported EBITDA.
Domino's India achieved 5% LFL growth and 10.7% revenue growth, supported by 10% order growth.
Added 114 stores in Q3 across brands, reaching a total network of approximately 3,600 stores globally.
India gross margins expanded 52 bps sequentially to 74.9% despite inflation in dairy, oil, and flour.
Popeyes delivered high double-digit LFL growth for the second consecutive quarter, reaching 73 stores.
💼 Action for Investors
Investors should note the successful margin expansion and the self-sustainability of international operations as key valuation drivers. The company's ability to maintain 5% LFL growth on a high base suggests strong brand resilience and effective product innovation.
Jubilant Pharmova's Montreal Facility Receives USFDA OAI Classification
Jubilant Pharmova's contract manufacturing facility in Montreal, Canada (CMO Montreal), has received an 'Official Action Indicated' (OAI) classification from the USFDA following an audit conducted in October and November 2025. An OAI status typically implies that the regulator may withhold approvals for new products from the site until issues are resolved. However, the company has already implemented remediation measures and resumed production operations at the facility in Q4'FY26. The company continues to work closely with the USFDA to address the specific audit observations.
Key Highlights
USFDA classifies CMO Montreal facility as Official Action Indicated (OAI) following late 2025 audit
Production operations at the site have successfully resumed in Q4'FY26 after remediation efforts
The facility is a strategic alliance under Jubilant HollisterStier, focusing on sterile injectables and ophthalmics
Jubilant Pharmova is working with the USFDA to resolve all outstanding regulatory observations
💼 Action for Investors
Investors should monitor the timeline for the USFDA to upgrade the facility's status from OAI, as this classification can delay new product launches. While the resumption of production is a positive operational step, the regulatory risk remains until a successful re-inspection or close-out letter is received.
UBL Gratuity Trust Tax Demand Reduced from ₹102.4 Cr to ₹3.21 Cr
United Breweries Limited (UBL) has reported a significant reduction in a tax demand related to its Gratuity Trust for AY 2022-23. Following a Karnataka High Court intervention, the National Faceless Assessment Centre (NFAC) revised the initial demand of ₹102.44 crore down to ₹3.21 crore. While the NFAC granted relief on capital contribution disallowances, it sustained a smaller exemption disallowance of ₹6.25 crore. The company intends to appeal the remaining ₹3.21 crore demand, which includes ₹2.18 crore in tax and ₹1.03 crore in interest.
Key Highlights
Initial tax demand of ₹1,024,400,466 (₹102.4 Cr) drastically reduced to ₹32,109,412 (₹3.21 Cr)
Relief granted by NFAC following a remand order from the Karnataka High Court regarding capital contributions
Remaining demand consists of ₹2.18 crore in tax and ₹1.03 crore in interest charges
A disallowance of exemption amounting to ₹6.25 crore was sustained by the tax authorities in the fresh order
The Trust plans to file an appeal before the Commissioner of Income Tax (Appeals) to contest the remaining balance
💼 Action for Investors
Investors should view this as a positive development as it significantly reduces a potential contingent liability. The remaining amount is immaterial to UBL's overall financial health, but the successful litigation demonstrates a strong legal defense.
UBL Q3 FY26 Results: PAT Jumps 111% to ₹81 Cr with Strong Margin Expansion
United Breweries Limited (UBL) reported a robust 111% YoY increase in Profit After Tax (PAT) to ₹81 crore for Q3 FY26. Despite a 1.3% dip in overall volumes due to a severe winter, net sales rose 4% to ₹2,071 crore, fueled by price hikes and a better product mix. Gross margins improved significantly by 222 bps to 45.3%, while EBIT grew 86% to ₹167 crore. The company's premiumization strategy is yielding results, with YTD premium volumes up 23%.
Key Highlights
Net Sales increased 4% YoY to ₹2,071 crore, driven by a 5% improvement in price and mix.
PAT surged 111% to ₹81 crore, and EBIT rose 86% to ₹167 crore.
Gross Margin expanded by 222 bps to 45.3% through cost efficiencies and price increases.
Premium portfolio continues to outperform with 23% YTD volume growth.
Strong performance in the West region (+20% volume) offset declines in the North (-16%).
💼 Action for Investors
Investors should focus on the strong margin recovery and premiumization trend, which are offsetting temporary weather-related volume softness. The stock remains a solid play on the long-term growth of the Indian beer market and operational efficiencies.
UBL Q3 FY26 PAT Surges 111% YoY to ₹80.8 Crore Despite Revenue Decline
United Breweries Limited (UBL) reported a significant 111% year-on-year increase in net profit for Q3 FY26, reaching ₹80.8 crore compared to ₹38.3 crore in the previous year. Although gross revenue from operations declined by 11% to ₹3,935.6 crore, the company demonstrated strong margin improvement and cost control. Earnings per share (EPS) rose to ₹3.06 from ₹1.45. Additionally, the company is moving toward resolving its Bihar plant deadlock by applying under the Amnesty Policy 2025 to restart non-alcoholic beverage production.
Key Highlights
Net Profit (PAT) grew 111% YoY to ₹80.8 crore for the quarter ended December 31, 2025.
Gross Revenue from operations stood at ₹3,935.6 crore, a decrease from ₹4,424.7 crore in Q3 FY25.
Profit Before Tax (PBT) nearly doubled to ₹131.9 crore from ₹61 crore in the corresponding quarter last year.
Exceptional items of ₹18.7 crore were recorded, primarily due to the impact of new Labour Codes.
The company received in-principle approval from BIADA to restart Bihar operations under the Amnesty Policy 2025.
💼 Action for Investors
Investors should view the strong bottom-line growth and margin expansion favorably, despite the revenue dip. Monitor the final resolution of the CCI penalty appeal and the successful restart of the Bihar unit as future catalysts.
Jubilant Foodworks Q3FY26: Consolidated PAT Jumps 94% YoY; EBITDA Margins Expand to 19.8%
Jubilant Foodworks reported a strong Q3FY26 with consolidated revenue growing 13.3% YoY to Rs. 24,372 mn. Profitability saw a significant boost as consolidated PAT (before exceptional items) surged 93.9% to Rs. 981 mn, driven by margin expansion and robust international performance. The company added 114 stores globally during the quarter, bringing the total network to 3,594 stores. Domino's India maintained momentum with its 8th consecutive quarter of positive Like-for-Like (LFL) growth at 5%.
Key Highlights
Consolidated EBITDA grew 20% YoY to Rs. 4,823 mn with margins expanding 110 bps to 19.8%.
Domino's India recorded 5% LFL growth and 9.6% order growth, with delivery contributing 74.9% of the sales mix.
International segment (Turkey) showed robust performance with revenue of Rs. 5,801 mn and PAT growth of 202% YoY.
Network expansion continued with 114 net store additions in Q3, including 75 Domino's stores in India.
Standalone PAT (before exceptional) grew 27.4% YoY to Rs. 793 mn, supported by a 121 bps QoQ expansion in EBITDA margins.
💼 Action for Investors
Investors should take note of the strong margin recovery and consistent LFL growth in the core India business. The turnaround in international operations and successful scaling of newer brands like Popeyes strengthen the long-term growth outlook.
Jubilant Foodworks Q3FY26: Consolidated PAT Surges 93.9% YoY to Rs. 981 Million
Jubilant Foodworks reported a strong Q3FY26 with consolidated revenue growing 13.3% YoY to Rs. 24,372 million. Profitability saw a significant boost as PAT from continued operations jumped 93.9% to Rs. 981 million, supported by a 110 bps expansion in EBITDA margins to 19.8%. The company accelerated its expansion, adding a record 114 net new stores, bringing the total global count to 3,594. Domino's India recorded a healthy 5.0% LFL growth, while the Turkey business showed exceptional performance with PAT growing over 200% YoY.
Key Highlights
Consolidated Revenue from operations increased 13.3% YoY to Rs. 24,372 million.
Consolidated EBITDA grew 20.0% YoY to Rs. 4,824 million with margins expanding 110 bps to 19.8%.
PAT from continued operations before exceptional items surged 93.9% YoY to Rs. 981 million.
Added 114 net new stores globally, including 75 new Domino's and 5 new Popeyes stores in India.
Domino's India reported 5.0% LFL growth and monthly transacting users reached 5.7 million, up 21% YoY.
💼 Action for Investors
The strong margin expansion and robust LFL growth in a competitive QSR market suggest improved operational efficiency and brand strength. Investors should maintain a positive outlook while monitoring the scaling of the Popeyes brand and the sustainability of international growth.
Jubilant Foodworks Q3 FY26 Standalone PAT Rises 31.7% YoY to ₹54.1 Cr; Revenue Up 11.8%
Jubilant Foodworks reported a steady performance for Q3 FY26 with standalone revenue reaching ₹1,801.5 crore, an 11.8% increase compared to the previous year. Standalone Net Profit grew significantly by 31.7% YoY to ₹54.1 crore, despite a one-time exceptional hit of ₹33.7 crore related to new Labour Code provisions. Operating margins showed resilience as Profit Before Exceptional Items grew by 37.4% YoY. The company continues to demonstrate top-line growth and operational efficiency in a competitive market.
Key Highlights
Standalone Revenue from operations grew 11.8% YoY to ₹18,015.1 million.
Standalone Net Profit (PAT) increased by 31.7% YoY to ₹540.8 million.
Recognized a one-time exceptional charge of ₹337.04 million due to the enactment of new Labour Codes.
Profit before exceptional items and tax stood at ₹1,082.6 million, a growth of 37.4% YoY.
Basic and Diluted EPS improved to ₹0.82 from ₹0.62 in the corresponding quarter last year.
💼 Action for Investors
Investors should focus on the strong 37% growth in operating profit before exceptional items, which indicates healthy underlying business momentum. The one-time labor code impact is non-recurring, making the core earnings performance attractive for long-term holders.
JUBLCPL Q3 FY26: Revenue Up 13%, 9M PAT Surges 50% with Agri Demerger and Expansion Plans
Jubilant Agri and Consumer Products Limited (JUBLCPL) reported a steady Q3 FY26 with consolidated revenue growing 13% YoY to 4,510 million. While Q3 PAT growth was muted at 1% due to exceptional items and margin pressure in polymers, the 9M FY26 performance remains strong with PAT rising 50% to 1,079 million. The company is pursuing a 50 crore capacity expansion in Performance Polymers and has approved a strategic demerger of its Agri Division to unlock shareholder value.
Key Highlights
9M FY26 Consolidated PAT grew 50% YoY to 1,079 million, while 9M EBITDA rose 41% to 1,665 million.
Agri Products segment revenue surged 34% YoY in Q3 FY26 to 1,654 million, supported by favorable monsoons.
Performance Polymers & Chemicals Q3 EBIT declined 23% YoY to 320 million due to global demand softness and higher input costs.
Approved 50 crore Capex to add 30,000 MTPA capacity at Samlya site, expected to be completed in 12 months.
Strategic demerger of Agri Division into Jubilant Agri Solutions Limited is underway to focus on core business verticals.
💼 Action for Investors
Investors should view the 9M growth and the proposed Agri demerger as positive catalysts for value unlocking. The company's low debt-to-equity ratio of 0.15x and expansion plans provide a strong foundation for long-term growth despite short-term margin volatility in the polymer segment.
Jubilant Ingrevia Q3 FY26: 9% Volume Growth, INR 2.5 Interim Dividend, EBITDA at INR 136 Cr
Jubilant Ingrevia reported stable Q3 FY26 revenue of INR 1,051 crore, supported by a 9% year-on-year volume growth that offset softer global pricing. The company declared an interim dividend of 250% (INR 2.5 per share) and highlighted a robust opportunity funnel of over 100 projects with a peak revenue potential of INR 3,500 crore. While quarterly EBITDA dipped 8% to INR 136 crore due to pricing headwinds, the 9-month EBITDA rose 8% to INR 436 crore. Management expects growth to accelerate in Q4 FY26, driven by the commencement of a major CDMO order and new capacity expansions.
Key Highlights
Achieved 9% YoY volume growth in Q3 FY26, marking the second-highest volumes in the last 12 quarters.
Declared an interim dividend of 250%, translating to INR 2.5 per equity share.
Specialty Chemicals segment maintained resilient margins above 25% despite intense global pricing pressure.
Secured 16 new molecule wins during the year with an estimated peak revenue potential of INR 1,400 crore.
Renewable energy share increased to 34%, contributing to a 10% YoY reduction in power and fuel expenses.
💼 Action for Investors
Investors should focus on the company's transition toward high-margin CDMO and specialty segments, with Q4 FY26 being a critical period for new order execution. The stock is a 'Watch' for signs of recovery in global chemical pricing which could further boost EBITDA margins.
Jubilant Foodworks Wins ITAT Appeal Quashing ₹190.21 Crore Tax Demand
Jubilant Foodworks has received a favorable order from the Income Tax Appellate Tribunal (ITAT) regarding a tax dispute for FY 2020-21. The ITAT has declared the assessment order void ab initio on the grounds of being time-barred, effectively quashing the pending tax demand. This demand was previously reduced from ₹216.19 Crores to ₹190.21 Crores following a rectification order in December 2025. While the tax department may seek further legal remedies, this ruling significantly reduces the company's contingent liabilities.
Key Highlights
ITAT declared the FY 2020-21 assessment order void ab initio as it was time-barred.
The ruling effectively removes a tax demand of ₹190.21 Crores.
The initial tax demand for the period was ₹216.19 Crores before a prior rectification.
The favorable outcome is subject to further appellate remedies available to the Income Tax Department.
💼 Action for Investors
This is a positive development that removes a significant legal and financial overhang for the company. Investors should remain aware of any potential appeals by the tax department in higher courts.
Jubilant Pharmova Q3 Revenue Rises 17% to Rs 2,123 Cr; CDMO Growth Offsets Montreal Shutdown
Jubilant Pharmova reported a solid 17% YoY revenue growth in Q3 FY26, reaching Rs 2,123 crore, driven by a 49% surge in the CDMO Sterile Injectables segment. However, normalized PAT declined by 17% to Rs 86 crore, and EBITDA margins contracted to 14.5% due to a temporary remediation-related shutdown at the Montreal facility. The company's leverage improved with Net Debt/EBITDA falling to 1.3x from 1.5x in the previous quarter. Management expects margin recovery in Q4 as production has resumed at the Montreal site and new capacities ramp up.
Key Highlights
Revenue grew 17% YoY to Rs 2,123 Cr, while 9M FY26 revenue reached Rs 5,990 Cr (up 13%).
CDMO Sterile Injectables revenue jumped 49% YoY to Rs 457 Cr, supported by the new Line 3 in Spokane.
EBITDA margins contracted by 172 bps YoY to 14.5% due to Montreal facility shutdown and remediation costs.
Ruby-Fill installation base grew by 37% in 9M FY26, significantly outpacing the 21% growth in FY25.
Generics business remained profitable for the third consecutive quarter with 13% revenue growth.
💼 Action for Investors
Investors should focus on the margin recovery trajectory in Q4 as the Montreal facility resumes operations and high-margin Radiopharma products scale. The strong top-line growth in CDMO and Radiopharma provides a positive long-term outlook despite temporary operational headwinds.
Jubilant Pharmova Q3 Standalone Net Profit Rises 24.5% YoY to ₹66 Million
Jubilant Pharmova reported a 20% YoY growth in standalone revenue to ₹673 million for the quarter ended December 31, 2025. Profit before tax from continuing operations saw a significant surge of 90% YoY, reaching ₹101 million, primarily driven by a sharp reduction in finance costs. The company successfully completed the slump sale of its API business to its subsidiary, Jubilant Biosys, on September 1, 2025, which is now reflected as discontinued operations. Total net profit for the quarter stood at ₹66 million, up from ₹53 million in the corresponding quarter of the previous year.
Key Highlights
Standalone revenue from operations increased 20% YoY to ₹673 million in Q3 FY26.
Profit before tax from continuing operations surged 90% YoY to ₹101 million.
Finance costs significantly decreased to ₹9 million from ₹33 million in the year-ago period.
The API business transfer was completed for a net asset value of ₹5,956 million on September 1, 2025.
Total comprehensive income for the period stood at ₹67 million versus ₹51 million YoY.
💼 Action for Investors
Investors should view the sharp reduction in finance costs and the restructuring of the API business as positive steps toward operational efficiency. Monitor the consolidated results for a clearer picture of the group's overall growth trajectory post-restructuring.
Jubilant Ingrevia Q3 FY26: PAT at ₹47 Cr; Declares ₹2.5 Interim Dividend Amid Pricing Pressure
Jubilant Ingrevia reported a mixed Q3 FY26 with revenue of ₹1,051 crore, down 1% YoY, as strong volume growth was offset by global pricing pressures. While quarterly PAT fell 32% YoY to ₹47 crore due to a one-time exceptional labor code expense, 9M FY26 performance remains positive with EBITDA up 8% YoY. The company declared an interim dividend of ₹2.5 per share (250%) and highlighted a robust CDMO pipeline with a peak revenue potential of ₹3,500 crore. Management remains optimistic about Q4, citing the commissioning of the $300 million Agro-Innovator project.
Key Highlights
Q3 FY26 Revenue stood at ₹1,051 Cr, with EBITDA margins holding steady at 13% despite global pricing headwinds.
Board declared an interim dividend of 250% (₹2.5 per equity share) for the financial year 2025-26.
CDMO pipeline expanded to 100+ active opportunities with a peak annual revenue potential of ₹3,500 Cr.
The $300 million Agro-Innovator project is on track for Q4 FY26 commissioning with dispatches starting March 2026.
Specialty Chemicals segment maintained resilient margins above 25% despite price volatility in Pyridine and Picolines.
💼 Action for Investors
Investors should focus on the upcoming commissioning of the Agro-Innovator project and the conversion of the ₹3,500 Cr CDMO pipeline as primary growth catalysts. While short-term pricing pressure persists, the company's volume growth and cost-efficiency measures provide a margin cushion.